The glucose-dependent nature of insulin secretion means that GLP-1 receptor agonists carry a lower risk of hypoglycaemia compared to some other diabetes medications, as they primarily work when blood sugar levels are elevated
Due to its sleep-related synthesis, the peptide has attracted attention for its potential role in regulating sleep patterns and promoting sleep-related well-being [1]
Semaglutide and tirzepatide reduced the risk of hospitalization for HFpEF and all-cause mortality by 40% compared to subjects who took the blood sugar medication sitagliptin, commonly sold under the brand name Januvia
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications primarily used to manage type 2 diabetes mellitus and, in some formulations, obesity
Men & Women trying to lean out while preserving muscle
Thus, when blood glucose increases, GLP-1 stimulates insulin secretion while decreasing glucagon secretion